Payment overview · 2025
General Payments
$3,600.07
225 reported records · 23 companies
Healthcare provider profile · identity verified
Benjamin John Wagner, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · AMHERST, NY · NPI 1447591565
Verified facts
What the public records show
CMS Open Payments records show Benjamin John Wagner, P.A. received $3,600.07 in general payments during 2025 across 225 reported records.
Neurocrine BioSciences, Inc. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Caplyta, Fanapt, Ingrezza, Lybalvi, Rexulti, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lybalvi by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RISPERDAL as an associated drug or biological on 125 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Risperdal by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trintellix by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $573.60 | 15.9% | 26 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $453.42 | 12.6% | 24 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $449.04 | 12.5% | 24 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $313.46 | 8.7% | 25 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $282.64 | 7.8% | 25 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $251.11 | 7.0% | 11 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $197.39 | 5.5% | 12 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $176.17 | 4.9% | 11 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $160.87 | 4.5% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.88 | 3.8% | 14 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $133.10 | 3.7% | 7 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $130.35 | 3.6% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $101.59 | 2.8% | 5 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $54.53 | 1.5% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $24.23 | 0.7% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $23.47 | 0.7% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.00 | 0.6% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.48 | 0.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.87 | 0.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.78 | 0.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.29 | 0.5% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17.72 | 0.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.08 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,600.07 | 225 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $573.60 | 26 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $572.35 | 39 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $453.42 | 24 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $251.11 | 11 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $197.39 | 12 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $169.78 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $160.87 | 22 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $155.38 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $143.59 | 16 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $139.05 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $135.88 | 14 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $133.23 | 8 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $133.10 | 7 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $110.70 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $101.59 | 5 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $84.68 | 4 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $54.53 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $23.47 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $20.79 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $2.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 112 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | RISPERDAL open payments reported associated product |
CMS Open Payments — General Payments 125 supporting records · 63 recipient NPIs · example record 1174300001 |
Risperdal · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Aripiprazole | Aripiprazole | 726 | 86 |
| Risperidone | Risperidone | 488 | 34 |
| Sertraline Hcl | Sertraline Hcl | 447 | 46 |
| Buspirone Hcl | Buspirone Hcl | 374 | 42 |
| Lamotrigine | Lamotrigine | 344 | 55 |
| Bupropion Xl | Bupropion Hcl | 290 | 41 |
| Olanzapine | Olanzapine | 283 | 28 |
| Clonazepam | Clonazepam | 260 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 239 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 224 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 207 | 22 |
| Trazodone Hcl | Trazodone Hcl | 197 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 31 |
| Lorazepam | Lorazepam | 167 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 149 | 16 |
| Divalproex Sodium | Divalproex Sodium | 147 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 25 |
| Ziprasidone Hcl | Ziprasidone Hcl | 125 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 123 | suppressed |
| Gabapentin | Gabapentin | 117 | 22 |
| Lithium Carbonate | Lithium Carbonate | 114 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 113 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 113 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 112 | 19 |
| Mirtazapine | Mirtazapine | 110 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 88 | 14 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 85 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 84 | 20 |
| Lurasidone Hcl | Lurasidone Hcl | 83 | 14 |
| Propranolol Hcl | Propranolol Hcl | 79 | 11 |
| Vraylar | Cariprazine Hcl | 73 | 12 |
| Clozapine | Clozapine | 72 | suppressed |
| Topiramate | Topiramate | 70 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | 13 |
| Alprazolam | Alprazolam | 63 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 62 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 60 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 51 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 44 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 43 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 38 | suppressed |
| Zonisamide | Zonisamide | 34 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Abilify Maintena | Aripiprazole | 31 | suppressed |
| Lexapro | Escitalopram Oxalate | 31 | suppressed |
| Clozapine Odt | Clozapine | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 25 | suppressed |
| Paliperidone Er | Paliperidone | 25 | suppressed |
| Caplyta | Lumateperone Tosylate | 24 | suppressed |
| Dayvigo | Lemborexant | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 19 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Olanzapine Odt | Olanzapine | 17 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Fanapt | Iloperidone | 14 | suppressed |
| Aristada | Aripiprazole Lauroxil | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Risperdal | Risperidone | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,600.07 · 225 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, HETLIOZ, INBRIJA, INGREZZA, Jornay PM, LYBALVI, QUTENZA, Qelbree, REXULTI, Radicava, SPRAVATO, SUBLOCADE, TRINTELLIX, UZEDY, VIVITROL, VRAYLAR, VYEPTI, WAINUA, WELLBUTRIN, Xeomin | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error